What's Happening?
The California Institute for Regenerative Medicine (CIRM) has granted $7.5 million to AcuraStem, a biotechnology company, to advance its lead clinical candidate, AS-241, towards first-in-human trials. AS-241 is an antisense oligonucleotide designed to address
the molecular consequences of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) by targeting the dysfunction of the protein TDP-43. This dysfunction leads to cryptic splicing of the UNC13A gene, affecting synaptic communication. The funding will support AcuraStem's efforts to move AS-241 into Phase 1 clinical trials, with preclinical studies showing promising results in restoring normal gene expression and improving synaptic function in ALS patient-derived neurons.
Why It's Important?
This funding is significant as it represents a major step forward in the development of treatments for ALS and FTD, diseases that currently have limited therapeutic options. The broad applicability of AS-241, which targets a common pathology in 97% of ALS patients, could potentially benefit a large patient population. The grant from CIRM, known for its rigorous review process, underscores the confidence in AcuraStem's research and the potential impact of AS-241. This development could lead to new, effective treatments for neurodegenerative diseases, improving the quality of life for many patients.
What's Next?
AcuraStem plans to use the CIRM funding to expedite the progression of AS-241 into Phase 1 clinical trials. The company will continue to leverage its iNeuroRx® technology platform to further validate the safety and efficacy of AS-241. As the trials progress, AcuraStem may seek additional partnerships and funding to support the broader development and potential commercialization of AS-241. The outcomes of these trials will be closely watched by the medical community and could influence future research and funding in the field of neurodegenerative diseases.
